Geo-enabled detect and respond system for antimalarial resistance in Ghana: GDRS - Ghana

加纳的抗疟药耐药性地理检测和响应系统：GDRS - 加纳

• 批准号: 10713339
• 负责人: Alash'le G. Abimiku
• 金额: --
• 依托单位: AKROS RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-11 至 2024-02-22
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10713339
• 关键词: Africa; African; Anti-malarial drug resistance; Antimalarials; Area; Blood; Cellular biology; Collaborations; Communities; Containment; Data; Data Science; Decision Making; Dryness; Early Diagnosis; Epidemiology; Field Workers; Genetic; Genomics; Geography; Ghana; HIV; Household; Human; Intervention; Investigation; Laboratories; Laboratory Research; Link; Malaria; Modeling; Molecular; Monitor; Nigeria; Patients; Pattern; Pharmaceutical Preparations; Plasmodium; Research; Research Personnel; Resistance; Sampling; Spottings; Strategic Planning; System; Translating; Treatment Failure; Vaccines; Visualization; Work; coronavirus disease; data streams; design; drug efficacy; epidemiologic data; genomic data; improved; innovation; insight; member; molecular marker; next generation sequencing; open source; pathogen; programs; research study; response; sociodemographics; spatiotemporal; surveillance data; surveillance network; tool; treatment guidelines; virology

Project summary Antimalarial drug resistance is a continuing challenge in the global effort to control and eliminate malaria. Well designed, rapid and highly granular antimalarial surveillance systems are urgently needed to protect the efficacy of remaining antimalarial treatments and inform discovery of new, effective drugs and vaccines. Molecular markers are useful tools to monitor anti-malarial drug resistance and, if used in routine surveillance, could help to detect and monitor the early emergence of resistance before it translates to treatment failures. This project will address the need for more powerful molecular surveillance through a strategic collaboration between two geographically and scientifically complementary, Africa-based networks - the DS-I Africa INFORM Research Hub and the West African Center for Cell Biology for Infectious Pathogens (WACCBIP). Akros and the Institute for Human Virology Nigeria, both part of the INFORM Research hub, will collaborate with WACCBIP to strengthen Ghana’s malaria genomic surveillance network to include capture of community-level, geo enabled dried blood spot (DBS) samples and expand this network to include additional epidemiologic and genomic data streams across geographies in Africa. This partnership will leverage WACCBIP’s existing genomic surveillance ‘hub-and-spoke’ lab network and integrate the network with the work of the DS-I Africa INFORM Research hub. The deliberate, strategic plan to integrate WACCBIP with partners within DS-I Africa will expand geographic coverage of geospatial surveillance through pivoting the open-source ‘Reveal’ geospatial platform already in use by DS-I Africa. With the use of Reveal, the consortium will geoenable WACCBIP’s existing malaria genomic surveillance network and expand the platform to link DBS data collected at the household level to advanced next generation sequencing (NGS) labs. Through this project, stakeholders will be equipped to visualize and monitor molecular markers of antimalarial resistance captured from the DBS samples, and geospatially align these genomic data to other data streams including epidemiologic, programmatic, and socio-demographic data to inform intervention response. The linking and geoenabling of the existing surveillance network to the Reveal platform will increase granular geospatial and temporal antimalarial resistance insights to guide responsive action and drive epidemiological understanding of antimalarial resistance emergence and spread. We envision this project will provide a model for a) geoenabled community-level genomic surveillance, b) better understanding of the manifestation of antimalarial resistance at a granular level, and c) timely access to critical evidence to guide national decision-making for malaria program response and adaptation.

项目摘要 抗疟药物耐药性是全球控制和消除疟疾努力中的一个持续挑战。精心设计， 迫切需要快速和高度颗粒化的抗疟监测系统，以保护剩余抗疟药物的有效性。 抗疟治疗和为发现新的有效药物和疫苗提供信息。分子标记是有用的工具， 监测抗疟疾药物耐药性，如果用于常规监测，可以帮助发现和监测早期疟疾。 在转化为治疗失败之前出现耐药性。 该项目将通过以下方面的战略合作来满足更强大的分子监测需求： 两个地理上和科学上互补的非洲网络--DS-I非洲INFORM研究中心 西非传染性病原体细胞生物学中心（WACCBIP）Akros和人类研究所 病毒学尼日利亚，都是INFORM研究中心的一部分，将与WACCBIP合作，加强加纳的疟疾 基因组监测网络，包括捕获社区一级的地理启用干血斑（DBS）样本， 扩大这一网络，以包括非洲各地理区域的其他流行病学和基因组数据流。这 该合作伙伴关系将利用WACCBIP现有的基因组监测“中心辐射”实验室网络， DS-I非洲信息研究中心的工作。 将WACCBIP与DS-I Africa内的合作伙伴整合在一起的深思熟虑的战略计划将扩大地理覆盖范围 通过将DS-I Africa已经使用的开源“Reveal”地理空间平台作为中心，实现地理空间监控。 通过使用Reveal，该联盟将对WACCBIP现有的疟疾基因组监测网络进行地理改造， 扩展平台，将家庭层面收集的DBS数据与先进的下一代测序（NGS）实验室联系起来。 通过这一项目，利益攸关方将能够可视化和监测抗疟药物耐药性的分子标志物 从DBS样本中捕获，并将这些基因组数据与其他数据流（包括流行病学， 方案和社会人口数据，为干预反应提供信息。将现有的 将监测网络与Reveal平台相结合，将增加精细的地理空间和时间抗疟耐药性 指导应对行动和推动流行病学对抗疟耐药性出现的认识， 传播. 我们设想这个项目将提供一个模型，a）地理启用社区级基因组监测，B）更好地 了解抗疟药物耐药性的具体表现，以及c）及时获得关键证据 指导国家疟疾方案应对和适应决策。